Q1 Earnings Forecast for Indivior Issued By HC Wainwright

Indivior PLC (NASDAQ:INDV) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Indivior in a report issued on Monday, January 12th. HC Wainwright analyst B. Folkes expects that the company will post earnings of $0.72 per share for the quarter. HC Wainwright has a “Buy” rating and a $48.00 price objective on the stock. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Indivior’s FY2026 earnings at $3.00 EPS, FY2027 earnings at $3.21 EPS, FY2028 earnings at $3.35 EPS and FY2029 earnings at $3.56 EPS.

INDV has been the topic of a number of other reports. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 3rd. Craig Hallum reiterated a “buy” rating and set a $41.00 price objective on shares of Indivior in a report on Friday, October 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. Morgan Stanley reaffirmed an “overweight” rating and set a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. Finally, Northland Securities set a $40.00 price target on Indivior in a research report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Indivior has a consensus rating of “Buy” and a consensus target price of $34.57.

Indivior Price Performance

Shares of INDV stock opened at $34.00 on Wednesday. The company has a market cap of $4.25 billion, a PE ratio of 36.96 and a beta of 0.75. Indivior has a 1 year low of $7.62 and a 1 year high of $38.00. The stock’s 50 day simple moving average is $34.26 and its two-hundred day simple moving average is $26.34.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. The business had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million.

Institutional Investors Weigh In On Indivior

Institutional investors have recently bought and sold shares of the company. Oaktree Capital Management LP grew its stake in shares of Indivior by 2,241.6% during the third quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock worth $6,215,206,000 after acquiring an additional 246,776,273 shares during the last quarter. Divisadero Street Capital Management LP increased its stake in Indivior by 2,372.5% during the 3rd quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock valued at $81,072,000 after purchasing an additional 3,226,605 shares in the last quarter. Goldentree Asset Management LP purchased a new position in shares of Indivior in the third quarter worth $42,630,000. Newtyn Management LLC lifted its stake in shares of Indivior by 61.1% during the third quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock worth $101,262,000 after buying an additional 1,592,982 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Indivior by 1,122.6% during the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock valued at $23,244,000 after buying an additional 1,447,939 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Mark Stejbach purchased 775 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director owned 16,847 shares in the company, valued at $596,215.33. This represents a 4.82% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Keith Humphreys purchased 775 shares of the stock in a transaction dated Monday, January 5th. The stock was purchased at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the acquisition, the director directly owned 5,802 shares in the company, valued at approximately $205,332.78. This represents a 15.42% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 4,871 shares of company stock worth $172,385 over the last ninety days.

Indivior News Summary

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $48 price target and published multi‑year forecasts that still show earnings growth into 2030 — this endorsement provides institutional support for the stock.
• Positive Sentiment: Majority analyst view remains constructive: Indivior was reported as having an average analyst rating of “Buy,” which underpins market confidence. Article Title
• Neutral Sentiment: Zacks highlighted Indivior in a market‑beating list — useful for sentiment and retail visibility but not a primary fundamental driver. Article Title
• Neutral Sentiment: HC Wainwright released granular quarterly EPS estimates for FY2026 (Q1–Q4) and interim quarters — provides updated guidance expectations but is informational rather than an immediate catalyst.
• Negative Sentiment: HC Wainwright trimmed several medium‑term EPS forecasts: FY2026 cut to $3.00 (from $3.22), FY2027 to $3.21 (from $3.43), FY2028 to $3.35 (from $3.56) and FY2029 to $3.56 (from $3.75). Those downward revisions signal slower profit acceleration than previously modeled and can weigh on the share multiple.
• Negative Sentiment: Short interest jumped materially in December to ~10.32M shares (about 8.3% of shares outstanding) — a 57.5% rise from mid‑December — which increases the potential for continued selling pressure and volatility while shorts remain elevated.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.